Drug Profile
Rotigotine transdermal - UCB
Alternative Names: Leganto; N-0437; N-0923; Neupro; Neupro Patch; Nubrenza; Rotigotine PR2.1.1; Rotigotine PR2.2.1; SPM-962Latest Information Update: 04 Jan 2024
Price :
$50
*
At a glance
- Originator Aderis Pharmaceuticals
- Developer Abbott Laboratories; Andromaco; Otsuka Pharmaceutical; UCB
- Class Antiparkinsonians; Small molecules; Tetrahydronaphthalenes; Thiophenes
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Parkinson's disease; Restless legs syndrome
- Discontinued Fibromyalgia
Most Recent Events
- 04 Jan 2024 No development reported - Phase-III for Restless legs syndrome (In adolescents) in USA (Transdermal) (NCT03728933) (UCB pipeline; January 2024)
- 01 Mar 2023 BioNxt Solutions plans a clinical trial for Parkinson's disease in Europe (Transdermal, Patch) in the second quarter of 2023
- 14 Apr 2021 Discontinued - Phase-II for Parkinson's disease in European Union (Intranasal) (UCB pipeline, April 2021)